or Try an Advanced Search...

    Technical Analysis for MYNZ - Mainz Biomed B.V.

    Grade Last Price % Change Price Change
    F 0.35 -13.92% -0.06
    MYNZ closed down 13.92 percent on Monday, July 1, 2024, on 2.12 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical MYNZ trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish -13.92%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -13.92%
    New 52 Week Low Weakness -13.92%
    Outside Day Range Expansion -13.92%
    Wide Bands Range Expansion -13.92%
    Oversold Stochastic Weakness -13.92%
    Older End-of-Day Signals for MYNZ ...

       Recent Intraday Alerts

    Alert Time
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 8 hours ago
    Fell Below Previous Day's Low about 8 hours ago
    New 52 Week Low about 8 hours ago
    2x Volume Pace about 9 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    MYNZ Chart by TradingView
    Basic chart:

    Profile

    Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Cancer Clinical Medicine Medical Genetics Medical Test Pancreatic Cancer Colorectal Cancer Diagnostic Tests Molecular Diagnostics Cancer Screening Innogenetics

    Is MYNZ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 4 Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
    Jun 3 Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
    May 31 Mainz Biomed Reports Results of 2024 Annual General Meeting
    May 29 Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    May 28 Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
    May 20 Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
    May 16 Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
    May 7 Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
    Apr 29 mRNA Is Promising A Breakthrough In Fighting Cancer
    Apr 25 Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
    See more MYNZ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.01
    52 Week Low 0.315
    Average Volume 283,653
    200-Day Moving Average 1.30
    50-Day Moving Average 0.68
    20-Day Moving Average 0.59
    10-Day Moving Average 0.46
    Average True Range 0.10
    RSI (14) 31.51
    ADX 26.12
    +DI 14.05
    -DI 29.28
    Chandelier Exit (Long, 3 ATRs) 0.72
    Chandelier Exit (Short, 3 ATRs) 0.60
    Upper Bollinger Bands 0.89
    Lower Bollinger Band 0.28
    Percent B (%b) 0.11
    BandWidth 104.44
    MACD Line -0.09
    MACD Signal Line -0.07
    MACD Histogram -0.0216
    Fundamentals Value
    Market Cap 7.03 Million
    Num Shares 20.4 Million
    EPS -1.92
    Price-to-Earnings (P/E) Ratio -0.18
    Price-to-Sales 24.92
    Price-to-Book 6.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.46
    Resistance 3 (R3) 0.47 0.43 0.44
    Resistance 2 (R2) 0.43 0.40 0.43 0.44
    Resistance 1 (R1) 0.39 0.38 0.37 0.39 0.43
    Pivot Point 0.35 0.35 0.34 0.35 0.35
    Support 1 (S1) 0.31 0.32 0.29 0.31 0.26
    Support 2 (S2) 0.27 0.30 0.27 0.25
    Support 3 (S3) 0.23 0.27 0.25
    Support 4 (S4) 0.23